Amphotericin B liposome preparation

• US 5,965,156 A
• Filed: 06/06/1995
• Issued: 10/12/1999
• Est. Priority Date: 11/12/1987
• Status: Expired due to Term

• Current Assignee: NeXstar Pharmaceuticals, Inc. (Gilead Sciences Inc.)
• Original Assignee: NeXstar Pharmaceuticals, Inc. (Gilead Sciences Inc.)
• Inventors: Chiang, Su-Ming, Proffitt, Richard T., Adler-Moore, Jill
• Primary Examiner(s): Peselev, Elli
• Application Number:
  US08/469,251
• Time in Patent Office: 1,589 Days
• Field of Search: 424/450, 514/31, 536/6.5
• US Class Current: 424/450
• CPC Class Codes: A61K 31/7048 having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin , digitoxin or digoxin
• CPC Class Codes: A61K 47/544 Phospholipids
• CPC Class Codes: A61K 9/1277 Processes for preparing; Proliposomes
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: B82Y 5/00 Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

A novel composition and method for solubilizing amphiphilic drugs in a small amount of organic solvent for use in improved liposomes is disclosed. A phosphatidylglycerol is acidified in a small amount of organic solvent. The amphiphilic drug, such as Amphotericin B, suspended in organic solvent is then added to the acidified phosphatidylycerol and a soluble complex is formed between the phosphatidylglycerol and the amphiphilic drug. When the liposome composition incorporating the soluble complex is hydrated, the final pH of the hydrating aqueous buffer is carefully controlled. The Amphotericin B liposomes formed have markedly reduced toxicity.

Claims

1. A process for solubilizing a polyene antibiotic, comprising forming a soluble complex between the polyene antibiotic and a phosphatidylglycerol in an acidified organic solvent and maintaining said soluble complex at a pH of 4.5 or less.

2. The process of claim 1 in which the soluble complex is formed in an organic solvent having a pH of from about 1.0 to about 3.0.

3. The process of claim 1 or 2 in which the phosphatidylglycerol is selected from the group consisting of distearoylphosphatidylglycerol, dilaurylphosphatidylglycerol, and dimyristoylphosphatidylglycerol.

4. The process of claim 1 or 2 in which the polyene antibiotic is amphotericin B.

5. The process of claim 3 in which the polyene antibiotic is amphotericin B.

6. The process of claim 4 in which the phosphatidylglycerol is distearoylphosphatidylglycerol.

7. A process for the formation of liposomes containing a polyene antibiotic, comprising forming a soluble complex between a polyene antibiotic and a phosphatidylglycerol in an acidified organic solvent and maintaining said soluble complex at a pH of 4.5 or less, removing the organic solvent to form a dried complex, and hydrating the dried complex with an aqueous buffer solution to form liposomes having a diameter of less than 2.0 μ

m.

8. The process of claim 7 in which the complex is formed in an organic solvent having a pH of form 1.0 to 3.0.

9. The process of claim 7 or 8 in which the phosphatidylglycerol is selected from the group consisting of distearoylphosphatidylglycerol, dilaurylphosphatidylglycerol, and dimyristoylphosphatidylglycerol.

10. The process of claim 7 or 8 in which a sterol is included with the soluble complex to form liposomes containing a polyene antibiotic and a sterol.

11. The process of claim 9 in which a sterol is included with the soluble complex to form liposomes containing a polyene antibiotic and a sterol.

14. The process of claim 10 wherein said sterol is cholesterol.

15. The process of claim 11 wherein said sterol is cholesterol.

16. A method for the treatment of a disseminated fungal infection comprising administering a therapeutically effective amount of the liposome prepared according to the process of claim 7.

12. The soluble complex of a polyene antibiotic and a phosphatidylglycerol, maintained in an acidified organic solvent having a pH of 4.5 or less.

13. The complex of claim 12 in which the polyene antibiotic concentration is greater than 25 mg of antibiotic per milliliter of solvent.